DataSheet1_Dendrobium candidum polysaccharide reduce atopic dermatitis symptoms and modulate gut microbiota in DNFB-induced AD-like mice.docx

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a high prevalence worldwide. Increasing evidence suggests that the gut microbiota plays an important role in the pathogenesis of AD. In this study, we sought to verify the effect of Dendrobium candidum polysaccharides (DCP) on AD induced by 2,4-Dinitrofluorobenzene (DNFB) in Balb/c mice regarding its impact on the intestinal microbiome. We found that 2-week oral administration of DCP improved AD-like symptoms and histological damage of skin, reduced mast cell infiltration, down-regulated the level of serum total IgE and the expression of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-4 and IL-6, and increased the expression level of anti-inflammatory cytokine IL-10. The beneficial effect of DCP was attributed to the restoration of the intestinal microbiome composition and the unbalance of the intestinal homeostasis. Our results indicated that DCP might be used as a promising novel microbiota-modulating agent for the treatment of AD.

特应性皮炎（Atopic Dermatitis，AD）是一种在全球范围内高发的慢性炎症性皮肤病。日益增多的研究证据表明，肠道菌群在AD的发病机制中扮演着关键角色。本研究旨在验证铁皮石斛多糖（Dendrobium candidum polysaccharides，DCP）对2,4-二硝基氟苯（2,4-Dinitrofluorobenzene，DNFB）诱导的Balb/c小鼠AD模型的干预效果，并探讨其对肠道微生物组的影响。研究发现，为期2周的DCP口服给药可改善小鼠类AD皮肤症状与皮肤组织学损伤，减少肥大细胞浸润，下调血清总IgE水平以及肿瘤坏死因子-α（TNF-α）、干扰素-γ（IFN-γ）、白细胞介素-4（IL-4）、白细胞介素-6（IL-6）等促炎细胞因子的表达，同时上调抗炎细胞因子白细胞介素-10（IL-10）的表达水平。DCP的有益作用可归因于其对肠道微生物组组成的修复以及对肠道稳态失衡的改善。本研究结果提示，DCP有望成为一种极具潜力的新型菌群调控制剂，用于AD的治疗。